Work has included a project on equity investment opportunities in Chinese healthcare. Product involved an evaluation of the overall market and the changes inspired by healthcare reforms and the 12th Five-Year Plan, leading to identification and analysis of (i) growth segments of the market and (ii) those companies, local and foreign, poised to benefit from the growth.

Investment analysis provided on pan-European healthcare, primarily pharmaceuticals, serving wealth management client base. Coverage broadened from previous mid-cap pharma focus, returning to Big Pharma and adding new stocks in pharma (Meda), hybrid pharma-chemicals (Solvay) and med-tech (Nobel Biocare, Essilor), while returning to others (Shire, GSK, Sanofi-Aventis) not previously covered at Blue Oak Capital. Lead analyst on c. 12 stocks, but able to deliver investment advice across S&P’s… Show more Investment analysis provided on pan-European healthcare, primarily pharmaceuticals, serving wealth management client base. Coverage broadened from previous mid-cap pharma focus, returning to Big Pharma and adding new stocks in pharma (Meda), hybrid pharma-chemicals (Solvay) and med-tech (Nobel Biocare, Essilor), while returning to others (Shire, GSK, Sanofi-Aventis) not previously covered at Blue Oak Capital. Lead analyst on c. 12 stocks, but able to deliver investment advice across S&P’s entire coverage of c. 30 European healthcare stocks. Broader, more authoritative coverage brought increased contact with wealth managers. Collaboration with US analysts on global product. Show less

New, independent sell-side broker, publishing equity research from September 2005, and voted by Extel in 2006 as number two independent research provider. My focus was pan-European mid-cap pharma: 10 stocks with market capitalisation. c. €110bn in total; individual stocks primarily c. €2-25bn, though Bayer was €40bn and Newron Pharmaceuticals < €200m, including much new coverage. First client votes secured, several pharma corporate road-shows hosted in London, Edinburgh and Dublin, including… Show more New, independent sell-side broker, publishing equity research from September 2005, and voted by Extel in 2006 as number two independent research provider. My focus was pan-European mid-cap pharma: 10 stocks with market capitalisation. c. €110bn in total; individual stocks primarily c. €2-25bn, though Bayer was €40bn and Newron Pharmaceuticals < €200m, including much new coverage. First client votes secured, several pharma corporate road-shows hosted in London, Edinburgh and Dublin, including for Novo Nordisk, UCB, Lundbeck and Orion. London marketing slots arranged ahead of a second (subsequently pulled) share offering by Newron. Show less

I joined Paribas in 1996, and following corporate deals joined BNP Paribas in 2000 and then Exane BNP Paribas from April to November 2004. My stock coverage was consistently pan-European pharmaceuticals/healthcare; the specific stock coverage responsibilities changed dramatically over the period, but included all major European pharma companies sometime during the period. Sector head at times at both Paribas and BNP Paribas. Top ten ranking secured by BNP Paribas in the sector in Extel survey.